与玻璃体内注射福米韦生治疗巨细胞病毒性视网膜炎相关的可逆性靶心样黄斑病变

Reversible bull's-eye maculopathy associated with intravitreal fomivirsen therapy for cytomegalovirus retinitis.

作者信息

Stone T W, Jaffe G J

机构信息

Duke University Eye Center, Durham, North Carolina 27710, USA.

出版信息

Am J Ophthalmol. 2000 Aug;130(2):242-3. doi: 10.1016/s0002-9394(00)00495-5.

DOI:10.1016/s0002-9394(00)00495-5

PMID:11004306

Abstract

PURPOSE

To report two cases in which a bull's eye maculopathy developed after intravitreal injection of fomivirsen.

METHODS

Case reports.

RESULTS

A 50-year-old man with acquired immunodeficiency syndrome (AIDS) and refractory cytomegalovirus retinitis developed bull's-eye pigmentary changes in the macula of the right eye after initiating therapy with fomivirsen (Vitravene; CIBA Vision, Atlanta, Georgia) intravitreal injections. These pigmentary changes resolved upon cessation of treatment. A 36-year-old man with AIDS and refractory bilateral cytomegalovirus retinitis developed bull's-eye pigmentary changes in both eyes during bilateral intravitreal treatment with fomivirsen. Vision was not affected. These changes resolved after treatment with fomivirsen was stopped.

CONCLUSION

Fomivirsen, a new medication for the treatment of refractory cytomegalovirus retinitis, may cause a bull's-eye maculopathy in some patients. The bull's-eye maculopathy is reversible and does not appear to affect vision.

摘要

目的

报告两例玻璃体内注射福米韦生后发生靶心样黄斑病变的病例。

方法

病例报告。

结果

一名50岁获得性免疫缺陷综合征（AIDS）患者，患有难治性巨细胞病毒性视网膜炎，在用福米韦生（Vitravene；CIBA Vision，佐治亚州亚特兰大）进行玻璃体内注射治疗后，右眼黄斑出现靶心样色素沉着改变。停止治疗后，这些色素沉着改变消失。一名36岁患有AIDS和难治性双侧巨细胞病毒性视网膜炎的男性，在双侧玻璃体内注射福米韦生治疗期间，双眼出现靶心样色素沉着改变。视力未受影响。停止福米韦生治疗后，这些改变消失。